Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 7/20 | 0.73 |
| ▸ | HTR1B | P28222 | 7/20 | 0.73 |
| ▸ | HTR2C | P28335 | 6/20 | 0.73 |
| ▸ | HTR1A | P08908 | 6/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8111175 | 0.93 | HTR1A (0.71) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL7479049 | 0.90 | HTR1D (0.69) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL13209475 | 0.88 | HTR1A (0.73) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL13112624 | 0.88 | HTR1A (0.77) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL6643961 | 0.88 | HTR1A (0.73) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL7839523 | 0.88 | HTR1D (0.73) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL27684264 | 0.88 | HTR1D (0.73) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL24026446 | 0.85 | HTR1A (0.72) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| Rizatriptan SCHEMBL12802834 | 0.85 | HTR1A (1.00) | HTR1DHTR1BHTR2CHTR1AADRA2C | |
| SCHEMBL7083606 | 0.85 | HTR1A (0.69) | HTR1DHTR1BHTR2CHTR1AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1157390-C | Indole derivant | — | 2004-07-14 | — | — | CN | claimed |
| EP-0763032-B1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO INC (US) | 2003-10-15 | — | — | EP | claimed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | claimed |
| CN-1322725-A | Indole derivant | MERCK & CO INC (US) | 2001-11-21 | — | — | CN | claimed |
| CN-1228094-A | Palladium catalyzed indolization | MERCK & CO INC (US) | 1999-09-08 | — | — | CN | claimed |
| CN-1152920-A | Palladium-Catalyzed Ring Closure of Triazolyl Tryptamine | MERCK & CO INC (US) | 1997-06-25 | — | — | CN | claimed |
| EP-1796675-A4 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| CN-101035537-A | Compositions and methods for treating ocular diseases | MERCK & CO INC (US) | 2007-09-12 | — | — | CN | disclosed |
| EP-1796675-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006039252-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| CN-1157390-C | Indole derivant | — | 2004-07-14 | — | — | CN | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-0925302-A1 | PALLADIUM CATALYZED INDOLIZATION | Merck & Co., Inc. (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| WO-1998006725-A1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997042189-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| CN-1152920-A | Palladium-Catalyzed Ring Closure of Triazolyl Tryptamine | MERCK & CO INC (US) | 1997-06-25 | — | — | CN | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | HTR1D 3404/4885HTR1B 3286/4885HTR2C 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.